Eli Lilly Launches Phase 3 Trial of Remternetug for Early Symptomatic Alzheimer’s Disease in China

Intelligent Finance APP learned on February 22 that the China Drug Clinical Trial Registration and Information Publicity Platform showed that Eli Lilly (LLY.US) launched an international multicenter Phase 3 clinical trial (including China) to evaluate the safety and efficacy of subcutaneous injection of remternetug in treating early symptomatic Alzheimer's disease. Public data shows that remternetug is a new antibody drug targeting a subtype of amyloid protein called N3pG.

According to publicly available information from Eli Lilly and Company, remternetug (LY3372993) is a next-generation N3pG amyloid antibody that employs a flexible dosing regimen, including subcutaneous administration, to meet the varying needs of Alzheimer's disease patients. Previously, this product demonstrated deep plaque clearance consistent with amyloid reduction levels in a Phase 1b clinical trial and showed a favorable safety profile.

According to the Chinese Clinical Trial Registry and Information Disclosure Platform, this is a randomized, double-blind, parallel-group, international multicenter Phase 3 clinical trial initiated by Eli Lilly and Company. The primary objective is to evaluate the safety and efficacy of weekly subcutaneous administration of remternetug in subjects with early symptomatic Alzheimer's disease who have brain amyloid and tau pathology. The trial plans to enroll 1,300 participants globally, including 140 participants in China, with Dr. Jia Jianping, Chief Physician at Xuanwu Hospital of Capital Medical University, serving as the principal investigator in China.

In addition to remternetug, Eli Lilly's pipeline includes several innovative therapies for Alzheimer's disease at various stages of clinical development. For example, donanemab, which has been submitted for regulatory approval in the United States and is currently under review, is a monoclonal antibody targeting β-amyloid and has been designated as a breakthrough therapy in China; solanezumab (LY2062430), a monoclonal antibody targeting Aβ monomers, which has entered phase 3 clinical trials; and LY3372689, an O-GlcNAcase inhibitor in phase 2 clinical trials.